KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Equity Income: 2009-2021

Historic Equity Income for Biomarin Pharmaceutical (BMRN) over the last 10 years, with Sep 2021 value amounting to $177,000.

  • Biomarin Pharmaceutical's Equity Income rose 119.22% to $177,000 in Q3 2021 from the same period last year, while for Sep 2021 it was -$278,000, marking a year-over-year increase of 68.55%. This contributed to the annual value of -$6,000 for FY2020, which is 98.98% up from last year.
  • Per Biomarin Pharmaceutical's latest filing, its Equity Income stood at $177,000 for Q3 2021, which was up 201.14% from -$175,000 recorded in Q2 2021.
  • Over the past 5 years, Biomarin Pharmaceutical's Equity Income peaked at $1.1 million during Q4 2020, and registered a low of -$1.4 million during Q1 2021.
  • Its 3-year average for Equity Income is -$176,545, with a median of -$79,000 in 2020.
  • As far as peak fluctuations go, Biomarin Pharmaceutical's Equity Income surged by 519.57% in 2019, and later slumped by 1,654.55% in 2021.
  • Over the past 5 years, Biomarin Pharmaceutical's Equity Income (Quarterly) stood at -$523,000 in 2017, then spiked by 113.00% to -$46,000 in 2018, then skyrocketed by 519.57% to $193,000 in 2019, then surged by 454.92% to $1.1 million in 2020, then surged by 119.22% to $177,000 in 2021.
  • Its Equity Income was $177,000 in Q3 2021, compared to -$175,000 in Q2 2021 and -$1.4 million in Q1 2021.